Amicus Therapeutics (NASDAQ:FOLD) Insider Jeff Castelli Sells 76,158 Shares of Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) insider Jeff Castelli sold 76,158 shares of the stock in a transaction on Monday, November 24th. The stock was sold at an average price of $10.16, for a total transaction of $773,765.28. Following the transaction, the insider directly owned 439,318 shares in the company, valued at $4,463,470.88. The trade was a 14.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Amicus Therapeutics Price Performance

Shares of Amicus Therapeutics stock opened at $10.02 on Thursday. The stock has a market capitalization of $3.09 billion, a price-to-earnings ratio of -83.49 and a beta of 0.66. The company has a current ratio of 3.21, a quick ratio of 2.29 and a debt-to-equity ratio of 1.92. Amicus Therapeutics, Inc. has a 1-year low of $5.51 and a 1-year high of $10.57. The firm has a fifty day simple moving average of $8.73 and a 200-day simple moving average of $7.34.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.05. Amicus Therapeutics had a negative return on equity of 5.07% and a negative net margin of 6.67%.The company had revenue of $169.06 million for the quarter, compared to the consensus estimate of $165.24 million. During the same period last year, the business posted $0.10 earnings per share. The firm’s revenue was up 19.5% compared to the same quarter last year. Amicus Therapeutics has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Zacks Research upgraded Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. Needham & Company LLC upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Thursday, September 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Amicus Therapeutics in a report on Tuesday. JPMorgan Chase & Co. increased their target price on shares of Amicus Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Finally, The Goldman Sachs Group boosted their price target on Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a research note on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $16.57.

Institutional Investors Weigh In On Amicus Therapeutics

Large investors have recently bought and sold shares of the business. Jefferies Financial Group Inc. bought a new stake in shares of Amicus Therapeutics during the first quarter worth $1,533,000. Invesco Ltd. raised its holdings in Amicus Therapeutics by 4.1% during the 1st quarter. Invesco Ltd. now owns 2,661,394 shares of the biopharmaceutical company’s stock worth $21,717,000 after purchasing an additional 105,856 shares during the last quarter. Victory Capital Management Inc. lifted its position in Amicus Therapeutics by 47.4% during the 1st quarter. Victory Capital Management Inc. now owns 257,088 shares of the biopharmaceutical company’s stock valued at $2,098,000 after purchasing an additional 82,691 shares during the period. Capital Fund Management S.A. boosted its stake in shares of Amicus Therapeutics by 408.8% in the 1st quarter. Capital Fund Management S.A. now owns 312,561 shares of the biopharmaceutical company’s stock valued at $2,550,000 after purchasing an additional 251,134 shares during the last quarter. Finally, Jump Financial LLC boosted its stake in shares of Amicus Therapeutics by 101.8% in the 1st quarter. Jump Financial LLC now owns 406,168 shares of the biopharmaceutical company’s stock valued at $3,314,000 after purchasing an additional 204,941 shares during the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.